641569-96-2

Basic information

• Product Name: 3-[(Aminoiminomethyl)amino]-4-methylbenzoic acid ethyl ester mononitrate
• Synonyms: 3-[(Aminoiminomethyl)amino]-4-methylbenzoic acid ethyl ester mononitrate;3-[(AMinoiMinoMethyl)aMino]-4-Methylbenzoic acid ethyl ester Mon;Ethyl 3-guanidino-4-methylbenzoate nitrate;Ethyl 3-Carbamimidoylamino-4-methylbenzoate Nitrate;3-[(Aminoimethyl)amino]-4-methylbenzoic acid ethyl estermononitrate;((aminoiminomethyl)amino)-4-methylbenzoic acid ethyl ester mononitrate;ethyl 3-guanidino-4-methylbenzoate
• CAS NO: 641569-96-2
• Molecular Formula: C₁₁H₁₅N₃O₂*HNO₃
• Molecular Weight: 284.27
• Mol File: 641569-96-2.mol
• Article Data: 4

Chemical Properties

• Melting Point: 197.0 to 201.0 °C
• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 3-[(Aminoiminomethyl)amino]-4-methylbenzoic acid ethyl ester mononitrate(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[(Aminoiminomethyl)amino]-4-methylbenzoic acid ethyl ester mononitrate(641569-96-2)
• EPA Substance Registry System: 3-[(Aminoiminomethyl)amino]-4-methylbenzoic acid ethyl ester mononitrate(641569-96-2)

Safety Data

• Hazardous Substances Data: 641569-96-2(Hazardous Substances Data)

Usage

General Description

3-[(Aminoiminomethyl)amino]-4-methylbenzoic acid ethyl ester mononitrate is a chemical compound that is an ethyl ester of a mononitrate derivative of 3-[(aminoiminomethyl)amino]-4-methylbenzoic acid. It has a complex molecular structure that includes multiple functional groups, such as an amino group, a nitrate group, and a benzoic acid group. The compound is likely to be used in pharmaceutical or chemical research due to its unique structure and potential properties, possibly for its role in drug development or analysis. Further study and research are necessary to fully understand the potential applications and properties of this compound.

InChI:InChI=1/C11H15N3O2.HNO3/c1-3-16-10(15)8-5-4-7(2)9(6-8)14-11(12)13;2-1(3)4/h4-6H,3H2,1-2H3,(H4,12,13,14);(H,2,3,4)

Upstream product

• 420-04-2 CYANAMID 
• 41191-92-8 3-amino-4-methylbenzoic acid ethyl ester 
• 96-98-0 4-methyl-3-nitrobenzoic acid 
• 19013-15-1 ethyl 4-methyl-3-nitro-benzoate 
• 641569-95-1 C₁₁H₁₅N₃O₂ 
• 2458-12-0 3-amino-p-toluic acid 

Downstream Products

• 1205540-16-4 N-(3-bromo-5-(trifluoromethyl)phenyl)-4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)benzamide 
• 641570-12-9 C₂₀H₁₆N₆OS 

Relevant articles and documents

Method for preparing N-(5-carboxyl-2-methylphenyl)-4-(3-pyridine)-2-pyrilamine

The invention discloses a method for preparing N-(5-carboxyl-2-methylphenyl)-4-(3-pyridine)-2-pyrilamine. The method specifically comprises the following steps: step 1, carrying out ethyl esterification reaction on 3-nitro-4-methyl benzoic acid serving as an initial raw material to generate a compound 2; step 2, reducing nitro of the compound 2 through hydrogenation reduction reaction in the presence of palladium on carbon to generate a compound 3; step 3, reacting the compound 3 with a nitrile amine aqueous solution, and then carrying out base exchange to obtain a compound 4; step 4, carrying out cyclization between the compound 4 and a compound 6 to obtain a compound 7; and step 5, hydrolyzing the compound 7 under the action of an alkaline to generate a compound 8, namely N-(5-carboxyl-2-methylphenyl)-4-(3-pyridine)-2-pyrilamine. The method overcomes the defects that in the prior art such as long reaction time, low yield, high cost, difficulty for industrial production, and the like. A preparation method, which is high in yield, is environmentally-friendly, and is suitable for industrial production, is provided.

N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF

The present invention relates to a novel N-phenyl-2-pyrimidine-amine derivative represented by the above formula (1) and its salt showing a superior effect on cancer in warm-blooded animals, such as lung cancer, gastric cancer, colon cancer, pancreatic cancer, hepatoma, prostatic cancer, breast cancer, chronic or acute leukemia, hematologic malignancy, encephalophyma, bladder cancer, rectal cancer, cervical cancer, lymphoma, etc. The present invention also relates to a process for preparing the compound, and to a pharmaceutical composition for the treatment of the above various diseases, which comprises an effective amount of the compound as an active ingredient together with pharmaceutically acceptable inert carriers.